Molecular Imaging of Urogenital Diseases

Cho, Steve Y.; Szabó, Zsolt

doi:10.1053/j.semnuclmed.2013.10.008

Cited by 28 publications

(24 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiotracers that have received attention for this purpose include 11 C-choline, 18 F-fluoroethylcholine, 18 F-FACBC, and a host of molecules targeting prostate-specific membrane antigen (PSMA; also known as glutamate carboxy-peptidase) such as 68 Ga-PSMA-11 and 18 F-DCFPyL 61,62 . PSMA-targeted imaging has gained particular interest, as radiotracers targeting this cell surface protein have been shown in numerous reports to offer outstanding sensitivity for detecting small-volume sites of prostate cancer that are not detectable on conventional imaging 63 (FIG.…”

Section: Imaging Of Oligometastatic Prostate Cancermentioning

confidence: 99%

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations

et al. 2016

View full text Add to dashboard Cite

The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer. Until genomic data exist to provide a biological component to the definition of oligometastatic disease, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy can be performed in the metastatic setting with minimal risk of toxic effects. These therapies seem to decrease the need for subsequent palliative interventions, but insufficient data are available to draw reliable conclusions regarding their effect on survival. Thus, a protocol for clinicians to manage the patient presenting with oligometastatic prostate cancer would be a useful clinical tool.

show abstract

Section: Imaging Of Oligometastatic Prostate Cancermentioning

confidence: 99%

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations

et al. 2016

View full text Add to dashboard Cite

show abstract

“…More recently, 18 F-flouride PET/CT has been found to have improved sensitivity and specificity for sites of osseous metastatic involvement. Studies have demonstrated improved accuracy of 18 F-Flouride PET/CT over MDP SPECT/CT in PCa [57–59]. Increased fluoride uptake in malignant bone lesions reflects the increase in regional blood flow and bone turnover characterizing on bone metastases.…”

Section: Psma Pet In Primary Stagingmentioning

confidence: 99%

PSMA PET and Radionuclide Therapy in Prostate Cancer

Bouchelouche

Türkbey

Choyke

2016

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Prostate cancer (Pca) is the most common malignancy in men and a major cause of cancer death. Accurate imaging plays an important role in diagnosis, staging, restaging, detection of biochemical recurrence, and for therapy of PCa patients. Since no effective treatment is available for advanced PCa, there is an urgent need to develop new and more effective therapeutic strategies. In order to optimize treatment outcome, especially in high risk PCa patients, therapy of PCa is moving rapidly towards personalization. Medical imaging, including positron emission tomography (PET)/computed tomography (CT), plays an important role in personalized medicine in oncology. In the recent years, much focus has been on prostate specific membrane antigen (PSMA) as a promising target for imaging and therapy with radionuclides, since it is upregulated in most PCa. In the prostate, one potential role for PSMA PET imaging is to help guiding focal therapy. Several studies have shown great potential of PSMA PET/CT for initial staging, lymph node staging, and detection of recurrence of PCa, even at very low PSA values after primary therapy. Furthermore, studies have shown that PSMA PET/CT has a higher detection rate than choline PET/CT. Radiolabeled PSMA ligands for therapy show promise in several studies with metastatic PCa, and is an area of active investigation. The “Image and treat” strategy, with radiolabeled PSMA ligands, has the potential to improve the treatment outcome of PCa patients, and is paving the way for precision medicine in PCa. The aim of this review is to give an overview of recent advancement in PSMA PET and radionuclide therapy of PCa.

show abstract

“…Positron imaging tomography (PET) with 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG) has been used to detect PCa [2], but due to low sensitivity and overlap with prostatitis, prostatic hypertrophy, and radiotracer renal secretion and accumulation in the bladder, new PET radiotracers are highly desired [3]. Choline PET imaging, using [ 11 C]choline or [ 18 F]fluoroethylcholine, is more sensitive for detecting PCa than [ 18 F]FDG [4–7].…”

Section: Introductionmentioning

confidence: 99%

Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model

et al. 2017

View full text Add to dashboard Cite

Purpose The identification and targeting of biomarkers specific to prostate cancer (PCa) could improve its detection. Given the high expression of translocator protein (TSPO) in PCa, we investigated the use of [18F]VUIIS1008 (a novel TSPO-targeting radioligand) coupled with positron emission tomography (PET) to identify PCa in mice and to characterize their TSPO uptake. Procedures Ptenpc−/−, Trp53pc−/− prostate cancer-bearing mice (n = 9, 4–6 months old) were imaged in a 7T MRI scanner for lesion localization. Within 24 h, the mice were imaged using a microPET scanner for 60 min in dynamic mode following a retro-orbital injection of ~ 18 MBq [18F]VUIIS1008. Following imaging, tumors were harvested and stained with a TSPO antibody. Regions of interest (ROIs) were drawn around the tumor and muscle (hind limb) in the PET images. Time-activity curves (TACs) were recorded over the duration of the scan for each ROI. The mean activity concentrations between 40 and 60 min post radiotracer administration between tumor and muscle were compared. Results Tumor presence was confirmed by visual inspection of the MR images. The uptake of [18F]VUIIS1008 in the tumors was significantly higher (p < 0.05) than that in the muscle, where the percent injected dose per unit volume for tumor was 7.1 ± 1.6 % ID/ml and that of muscle was < 1 % ID/ml. In addition, positive TSPO expression was observed in tumor tissue analysis. Conclusions The foregoing preliminary data suggest that TSPO may be a useful biomarker of PCa. Therefore, using TSPO-targeting PET ligands, such as [18F]VUIIS1008, may improve PCa detectability and characterization.

show abstract

Molecular Imaging of Urogenital Diseases

Cited by 28 publications

References 144 publications

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations

Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations

PSMA PET and Radionuclide Therapy in Prostate Cancer

Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model

Contact Info

Product

Resources

About